MX2009010268A - Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. - Google Patents
Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.Info
- Publication number
- MX2009010268A MX2009010268A MX2009010268A MX2009010268A MX2009010268A MX 2009010268 A MX2009010268 A MX 2009010268A MX 2009010268 A MX2009010268 A MX 2009010268A MX 2009010268 A MX2009010268 A MX 2009010268A MX 2009010268 A MX2009010268 A MX 2009010268A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonist
- thrombin receptor
- reduction
- adverse events
- procedure
- Prior art date
Links
- 230000002411 adverse Effects 0.000 title abstract 2
- 239000003856 thrombin receptor antagonist Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 abstract 2
- 229960005044 vorapaxar Drugs 0.000 abstract 2
- 238000013152 interventional procedure Methods 0.000 abstract 1
- 238000013146 percutaneous coronary intervention Methods 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Se describen métodos para prevenir eventos clínicos adversos en un paciente que experimenta un procedimiento de intervención coronaria percutánea o un procedimiento de intervención percutánea periférica, que comprende administrar al paciente una cantidad terapéuticamente efectiva de un antagonista del receptor de trombina, tal como SCH 530348; la administración de una dosis de carga de aproximadamente 40 mg de SCH 530348 tan sólo una hora antes del procedimiento, puede dar como resultado niveles terapéuticamente efectivos de agregación de plaquetas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89673807P | 2007-03-23 | 2007-03-23 | |
| US93262807P | 2007-05-31 | 2007-05-31 | |
| US98505107P | 2007-11-02 | 2007-11-02 | |
| PCT/US2008/003601 WO2008118320A1 (en) | 2007-03-23 | 2008-03-19 | Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010268A true MX2009010268A (es) | 2009-11-09 |
Family
ID=39535699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010268A MX2009010268A (es) | 2007-03-23 | 2008-03-19 | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080234236A1 (es) |
| EP (1) | EP2134344A1 (es) |
| JP (1) | JP2010522169A (es) |
| AU (1) | AU2008230116A1 (es) |
| BR (1) | BRPI0809095A2 (es) |
| CA (1) | CA2681597A1 (es) |
| CL (1) | CL2008000821A1 (es) |
| MX (1) | MX2009010268A (es) |
| TW (1) | TW200908971A (es) |
| WO (1) | WO2008118320A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| US20090297576A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of PAR-1 Antagonists to Treat Vascular Complications |
| EP2396001A1 (en) * | 2009-02-12 | 2011-12-21 | Schering Corporation | Par-1 antagonism in fed or antacid-dosed patients |
| US20120121706A1 (en) | 2009-04-10 | 2012-05-17 | Tufts Medical Center, Inc. | PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
| JP2012529431A (ja) | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
| EP2488026A4 (en) * | 2009-10-02 | 2013-04-10 | Merck Sharp & Dohme | USE OF A PAR-1 ANTAGONIST IN COMBINATION WITH A P2Y12ADP RECEPTOR ANTAGONIST FOR INHIBITING THROMBOSE |
| US20140378502A1 (en) * | 2011-05-12 | 2014-12-25 | UNIVERSITé LAVAL | Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections |
| US9140684B2 (en) | 2011-10-27 | 2015-09-22 | University Of Washington Through Its Center For Commercialization | Device to expose cells to fluid shear forces and associated systems and methods |
| JP2016524156A (ja) * | 2013-06-26 | 2016-08-12 | ユニヴァーシティ オブ ワシントン センター フォー コマーシャライゼーション | 個別化された凝集測定のための流体素子 |
| DE102014108210A1 (de) * | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| FR3090317B1 (fr) * | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106197A (en) * | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5576328A (en) * | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| PT1294714E (pt) * | 2000-06-15 | 2007-11-06 | Schering Corp | Antagonistas do receptor de trombina |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| PE20030808A1 (es) * | 2001-10-18 | 2003-09-22 | Schering Corp | Derivados triciclicos heterociclicos como antagonistas receptores de trombina |
| DE60317493T3 (de) * | 2002-04-16 | 2018-07-12 | Merck Sharp & Dohme Corp. | Trizyklische thrombin rezeptor antagonisten |
| JP2009521472A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
-
2008
- 2008-03-19 BR BRPI0809095-5A patent/BRPI0809095A2/pt not_active IP Right Cessation
- 2008-03-19 EP EP08726976A patent/EP2134344A1/en not_active Withdrawn
- 2008-03-19 US US12/051,504 patent/US20080234236A1/en not_active Abandoned
- 2008-03-19 WO PCT/US2008/003601 patent/WO2008118320A1/en active Application Filing
- 2008-03-19 JP JP2009554562A patent/JP2010522169A/ja not_active Withdrawn
- 2008-03-19 AU AU2008230116A patent/AU2008230116A1/en not_active Abandoned
- 2008-03-19 MX MX2009010268A patent/MX2009010268A/es not_active Application Discontinuation
- 2008-03-19 CA CA002681597A patent/CA2681597A1/en not_active Abandoned
- 2008-03-20 TW TW097109938A patent/TW200908971A/zh unknown
- 2008-03-20 CL CL200800821A patent/CL2008000821A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2134344A1 (en) | 2009-12-23 |
| WO2008118320A1 (en) | 2008-10-02 |
| TW200908971A (en) | 2009-03-01 |
| BRPI0809095A2 (pt) | 2014-09-09 |
| US20080234236A1 (en) | 2008-09-25 |
| CA2681597A1 (en) | 2008-10-02 |
| CL2008000821A1 (es) | 2008-10-24 |
| AU2008230116A1 (en) | 2008-10-02 |
| JP2010522169A (ja) | 2010-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| JP2010525050A5 (es) | ||
| NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
| MY159353A (en) | Pirfenidone treatment for patients with atypical liver function | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
| WO2009043464A3 (en) | Astressin and beta- endorphin for use as therapeutic agents | |
| JP2015524444A5 (es) | ||
| EP3241840A3 (en) | Inhibition of axl signaling in anti-metastatic therapy | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| WO2009033760A3 (en) | Use of fibronectin fragment (196-203 ) as a therapeutic agent | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| JP2007119497A5 (es) | ||
| WO2009046860A3 (en) | Use of dago as a therapeutic agent | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |